Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Rectum Cancer: early-phase trial registry

2 of 5 indexed Rectum Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Rectum Cancer: 5 US clinical trials tracked, 2 recruiting.

Rectum Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 2 of these trials.

Enrollment posture brief

Registry condition rectum-cancer

OPEN 2 | RECR 40% | LATE 0 | EARLY 2 | RANK #3391 | SPON 2

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Rectum Cancer (this)40%
Open-enrollment share among volume-matched conditions near Rectum Cancer

Rectum Cancer lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Rectum Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Rectum Cancer is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Rectum Cancer research.

    University of Colorado, Denver accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Rectum Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 48 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Rectum Cancer research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22

Phase Distribution

PhaseTrial count
Phase 2 2

Named interventions

Most-linked intervention names on Rectum Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Biopsy Other
1 trials
Active control comparator Behavioral
1 trials
Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C) Behavioral
1 trials
CARES Intervention Behavioral
1 trials
Radiation Radiation
1 trials
Cabozantinib Drug
1 trials
Nivolumab Drug
1 trials
Oxaliplatin Drug
1 trials

US sites by state

Facility locations filed on Rectum Cancer trials. A trial with sites in several states counts in each.

Colorado 2 trials
Utah 1 trials
North Carolina 1 trials
Missouri 1 trials
Michigan 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Rectum Cancer page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rectum Cancer condition card totals 5 registered trials; most-linked intervention Biopsy; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.